secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-046817
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001
-------------------------------------------------------------------

- Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.
- Net proceeds of approximately $295.9M after underwriting discounts and expenses.
- Proceeds intended to fund operations into Phase 3 development of DMR-001.
- Underwriting agreement with Jefferies LLC and Leerink Partners LLC; closing expected February 12, 2026.
- Offering was made under an automatic shelf registration statement on Form S-3 (File No. 333-293343).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526046817/0001193125-26-046817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526046817/d38009d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-046817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer